Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BTI-A-404
Cat. No.:
OB0425LY-064
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by HPLC.
Size:
Add to basket
Product Overview
Description:
BTI-A-404 is a small molecule drug primarily used to inhibit specific cell signaling pathways.
Synonyms:
537679-57-5; 4-(4-(Dimethylamino)phenyl)-N-(3,5-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; 4-[4-(Dimethylamino)phenyl]-N-(3,5-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxamide
CAS No.:
537679-57-5
Compound CID:
2952084
Formula:
C22H26N4O2
Formula Weight:
378.47
Specification
Target:
Free fatty acid receptor
Pathway:
GPCR/G protein
Storage:
Storage at -20°C.
Applications:
BTI-A-404 plays a role in inflammation, obesity and type 2 diabetes research species.
